ArticleCancers2022
Differences in the Molecular Profile between Primary Breast Carcinomas and Their Cutaneous Metastases.
Article in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Discordance of PIK3CA mutational status between primary and metastatic breast cancer: a systematic review and meta-analysis.Breast cancer research and treatment · 2023Pooled it
- Postoperative cutaneous metastasis of breast cancer with phenotypic conversion to triple-negative subtype: A case report.Medicine · 2026Article
- Heterogeneity of Hormone Receptors and HER2 in Breast Cancer Cutaneous Metastases: An Institutional Experience.International journal of molecular sciences · 2026Article
- Single-nucleus RNA sequencing identifies a novel tenogenic heterologous differentiation in endometrial carcinosarcomas: implications for diagnosis and tumor classification.The Journal of pathology · 2026Article
- Ipsilateral Breast Carcinoma Recurrence: True Recurrence or New Primary? A Clinicopathologic and Molecular Study.The American journal of surgical pathology · 2025Article
- Article
- Systemic and locoregional therapies for cutaneous metastases from breast cancer: state of art and new frontiers in treatment approach.Therapeutic advances in medical oncology · 2025Review
- Case Report: Solitary scalp metastasis after surgery for invasive ductal carcinoma of the breast.Frontiers in oncology · 2025Article
- CDH1 methylation analysis in invasive lobular breast carcinomas with and without gene mutation.Virchows Archiv : an international journal of pathology · 2024Article
- Molecular alterations and prognosis of breast cancer with cutaneous metastasis.Diagnostic pathology · 2024Article
- Case report: A case of advanced gastric cancer with multiple skin metastases, with significant relief from immunotherapy.Frontiers in immunology · 2024Article
- Case report: Cutaneous metastases as a first manifestation from breast cancer with concurrent gastric metastases.Frontiers in pharmacology · 2024Article
- The Clonal Relationship Between the Ductal and Lobular Components of Mixed Ductal-Lobular Carcinomas Suggested a Ductal Origin in Most Tumors.The American journal of surgical pathology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe characterization of molecular alterations of primary breast carcinomas (BC) and their cutaneous metastases (CM) to identify genes involved in the metastatic process have not yet been completely accomplished.
methodsTo investigate the molecular alterations of BC and their CM, a total of 66 samples (33 BC and 33 CM) from 33 patients were analyzed by immunohistochemical and massive parallel sequencing analyses. In addition, the clinicopathological characteristics of patients and tumors were analyzed.
resultsTriple negative (TN) BCs were overrepresented (36.4%) among tumors that developed CM. A change of tumor surrogate molecular type in metastases was found in 15% of patients and 48.5% of the CM presented some additional molecular alteration with respect to the primary tumor, the most frequent were amplification of
conclusionsThe TN molecular type has a greater risk of developing skin metastases. There are phenotypic changes and additional molecular alterations in skin metastases compared to the corresponding primary breast tumors in nearly half of the patients. Although these changes do not follow a specific pattern and varied from patient to patient, they could impact on the treatment. More studies with larger patient and sample cohorts are needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.